El Saadany T, Lupatsch J, Mark M, Barbier M, Mehra T, Schwenkglenks M, von Moos R. A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. Swiss Med Wkly [Internet]. 2025 Jan. 6 [cited 2025 Feb. 18];155(1):3777. Available from: https://smw.ch/index.php/smw/article/view/3777